The Alzheimer's Drug Discovery Foundation to Host 12th International Conference on Alzheimer's Drug Discovery

NEW YORK, Aug. 22, 2011 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation will host the 12th International Conference on Alzheimer's Drug Discovery on September 26-27, 2011 at the Hyatt Regency in Jersey City, New Jersey.  The purpose of the conference is to bring together investigators intent on accelerating the development of treatments for Alzheimer's disease and related dementias. The Alzheimer's Drug Discovery Foundation's funded investigators and other scientists in the field will present their current research and create opportunities for networking. This annual meeting attracts over 160 academic, industry and government scientists from around the world.

This two-day global meeting is organized around four sub-topics: Targeting Tau for Alzheimer's Disease and Related Dementia; Inflammation, Chaperones and Novel Targets; Neuroprotection and Synaptic Enhancement; and Accelerating Clinical Trials for Alzheimer's Disease Through Biomarkers. 

"This year's conference is particularly timely," said Dr. Howard Fillit, ADDF's Executive Director.  "We are especially excited about the inclusion of the Accelerating Clinical Trials for Alzheimer's Disease Through Biomarkers section in this year's program.  With advances in basic science and experimental research rapidly bringing drug discovery closer to the clinic, it is more important than ever before to foster dialogue between preclinical and clinical researchers in the field and accelerate the translation of new knowledge to patients."

FOR CONFERENCE DETAILS AND TO REGISTER, please visit the conference website.  Group discounts are available! 

TO CO-SPONSOR OR EXHIBIT, please contact Filomena Machleder at [email protected]

About the Alzheimer's Drug Discovery Foundation (ADDF)
The ADDF ( is the only public charity whose sole mission is to accelerate the discovery and development of drugs to prevent, treat and cure Alzheimer's Disease, related dementias and cognitive aging. Since 1998, the ADDF has granted more than $45 million to fund over 325 Alzheimer's drug discovery programs in academic centers and biotechnology companies in 18 countries.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.